Overview
Mermaid diagram (expand to render)
NCT06014424 is a Phase 2 clinical trial investigating the efficacy of cannabidiol (CBD) for managing agitation in [Alzheimer's disease](/diseases/alzheimers-disease) patients. The study is conducted at Sunnybrook Health Sciences Centre in Toronto, Canada, representing a significant investigation into non-psychotropic cannabinoid therapy for behavioral symptoms in neurodegenerative disease["@agganci2019"].
Agitation represents one of the most challenging aspects of Alzheimer's disease care, affecting approximately 50-80% of patients at some point during disease progression. This symptom significantly impacts quality of life for both patients and caregivers, often leading to institutionalization and increased healthcare costs.
Trial Details
| Attribute | Value |
|-----------|-------|
| NCT ID | NCT06014424 |
| Phase | Phase 2 |
| Status | Recruiting |
| Study Type | Interventional |
| Design | Cross-over trial |
| Intervention | CBD capsules |
| Indication | Agitation in Alzheimer's Disease |
| Sponsor | Sunnybrook Health Sciences Centre |
| Location | Toronto, Ontario, Canada |
Background: Agitation in Alzheimer's Disease
Definition and Prevalence
Agitation in dementia encompasses a spectrum of behaviors including restlessness, pacing, verbal aggression, physical aggression, and disinhibition. According to the Cohen-Mansfield Agitation Inventory (CMAI), these behaviors are categorized into physically non-aggressive behaviors (pacing, inappropriate robing), verbally aggressive behaviors (screaming, complaining), and physically aggressive behaviors (hitting, kicking)[@egaert2019].
The prevalence of agitation increases with disease severity:
- Mild AD: 30-40% experience agitation
- Moderate AD: 50-60% experience agitation
- Severe AD: 70-80% experience agitation
Impact on Caregiving
Agitation is a leading cause of caregiver burnout and institutionalization:
Caregiver stress: Constant vigilance and management of agitation leads to physical and emotional exhaustion
Safety concerns: Aggressive behaviors pose risks to both patient and caregiver
Economic burden: Behavioral symptoms account for up to 40% of dementia care costs
Quality of life: Agitation significantly diminishes quality of life for patients and familiesCurrent Treatment Landscape
Non-pharmacological approaches are first-line treatment:
- Environmental modifications
- Music therapy
- Pet therapy
- Structured activities
- Caregiver education
Pharmacological options are limited and often suboptimal:
- Antipsychotics: Black box warning for increased mortality
- Benzodiazepines: Risk of sedation, falls, cognitive worsening
- Antidepressants: Variable efficacy, side effects
- Acetylcholinesterase inhibitors: Modest benefit for some patients
This underscores the urgent need for novel therapeutic approaches with better safety profiles.
Study Description
Rationale for CBD
Cannabidiol (CBD) has emerged as a promising candidate for managing behavioral symptoms in dementia for several reasons[@watt2017]:
Non-psychotropic properties: Unlike tetrahydrocannabinol (THC), CBD does not produce psychoactive effects, making it suitable for elderly patients with cognitive impairment.
Multiple mechanisms of action: CBD interacts with numerous receptor systems implicated in agitation:
- Endocannabinoid system modulation (CB1, CB2 receptors)
- Serotonin 5-HT1A receptor agonism
- PPAR-gamma nuclear receptor activation
- TRPV1 vanilloid receptor modulation
- Anti-inflammatory effects via COX-2 inhibition
Safety profile: CBD has been shown to have a favorable safety profile in clinical trials, with mild to moderate side effects including dry mouth, drowsiness, and diarrhea.
Preclinical Evidence
Several preclinical studies support CBD's potential for neurodegenerative applications[@mishra2012]:
- Neuroprotection: CBD protects against amyloid-beta induced neurotoxicity in vitro
- Anti-inflammatory: Reduces microglial activation and pro-inflammatory cytokines
- Antioxidant: Scavenges free radicals and reduces oxidative stress
- Anti-apoptotic: Prevents neuronal cell death in cellular models
Clinical Evidence
While direct clinical trial data for CBD in Alzheimer's agitation is limited, related evidence exists[@kumar2021]:
- Dementia-related behaviors: Small studies show THC/CBD combinations may reduce agitation
- Parkinson's disease: CBD has been studied for psychosis and motor symptoms
- Epilepsy: CBD safety established in thousands of pediatric and adult patients
- Anxiety: CBD demonstrates anxiolytic effects in clinical trials
Proposed Mechanism in Agitation
CBD may address agitation through multiple pathways[@cohen2022]:
Anxiolytic effects: 5-HT1A receptor agonism reduces anxiety, a common trigger for agitation
Sleep regulation: CBD may improve sleep-wake cycles disrupted in dementia
Anti-inflammatory: Neuroinflammation contributes to behavioral symptoms
Neuroprotection: May slow underlying neurodegeneration affecting behavior regulationStudy Design
Cross-over Methodology
The cross-over design offers several advantages for this trial:
Within-patient comparison: Each patient serves as their own control, eliminating inter-individual variability.
Efficient sample size: Fewer participants needed compared to parallel-group designs.
Treatment sequence: Patients receive both CBD and placebo in randomized order, with washout periods between treatments.
Blinding: Both patients and investigators are blinded to treatment allocation until trial completion.
Treatment Protocol
| Phase | Duration | Treatment |
|-------|----------|-----------|
| Baseline | 2 weeks | Screening/washout |
| Period 1 | 8 weeks | CBD or placebo |
| Washout | 2 weeks | Medication-free |
| Period 2 | 8 weeks | Alternate treatment |
Dosage Considerations
CBD dosing in clinical trials varies widely:
- Low dose: 10-20 mg/day
- Medium dose: 50-100 mg/day
- High dose: 200-500 mg/day
The optimal dose for agitation will be determined through dose-escalation components of the trial.
Outcome Measures
Primary Endpoints
| Measure | Scale | Description |
|---------|-------|-------------|
| Agitation | CMAI | Cohen-Mansfield Agitation Inventory |
| Behavior | NPI | Neuropsychiatric Inventory |
| Response | CGI-C | Clinical Global Impression of Change |
Secondary Endpoints
- Sleep quality (actigraphy, sleep diaries)
- Caregiver burden (Zarit Burden Interview)
- Cognitive function (MMSE, ADAS-Cog)
- Safety and tolerability
- Quality of life (QoL-AD)
Exploratory Endpoints
- Biomarker collection (inflammatory markers)
- Pharmacokinetic sampling
- Adverse event monitoring
Inclusion Criteria
Key inclusion criteria:
Clinical diagnosis of Alzheimer's disease
Clinically significant agitation (CMAI score >= 25)
Age 60-90 years
Stable AD medications (if any) for >=4 weeks
Available caregiver/informant
Able to swallow capsulesExclusion Criteria
Key exclusion criteria:
Prior cannabis use disorder
Significant liver dysfunction (elevated LFTs >3x ULN)
Current use of CBD or cannabis products
Severe medical conditions
Psychotic disorders unrelated to dementia
Contraindications to study proceduresSafety Considerations
CBD Safety Profile
CBD is generally well-tolerated with a favorable safety profile:
| Adverse Event | Frequency | Severity |
|---------------|-----------|----------|
| Drowsiness | 10-20% | Mild-moderate |
| Dry mouth | 5-15% | Mild |
| Diarrhea | 5-10% | Mild |
| Nausea | 3-8% | Mild |
| Liver enzyme elevation | 2-5% | Mild-moderate |
Drug Interactions
CBD may interact with certain medications through CYP450 enzyme inhibition:
- Warfarin: May increase INR
- Anticonvulsants: May alter levels
- Antidepressants: May increase levels of some SSRIs
- Antipsychotics: May increase levels of some agents
Special Populations
Elderly patients require careful monitoring:
- Start low, go slow dosing strategy
- Renal and hepatic function monitoring
- Orthostatic hypotension precautions
- Fall risk assessment
Clinical Implications
Potential Benefits
If successful, this trial could provide:
Novel treatment option: First evidence-based CBD formulation for AD agitation
Improved safety: Better side effect profile than antipsychotics
Natural product appeal: Patient/caregiver preference for plant-based options
Disease-modifying potential: Neuroprotective effects may slow progressionChallenges
Several challenges remain:
- Variable response: Individual variability in CBD metabolism
- Dosing optimization: Finding optimal dose for geriatric population
- Long-term effects: Unknown effects with extended use
- Regulatory status: CBD remains controlled substance in some jurisdictions
Regulatory Considerations
FDA Status
CBD products occupy a complex regulatory space:
- Epidiolex (CBD for epilepsy) is FDA-approved
- CBD in dietary supplements remains legally uncertain
- CBD for neurological indications requires prescription
Health Canada Context
As the trial is conducted in Canada, Health Canada regulations apply:
- CBD is legal for medical purposes with prescription
- Product quality and consistency are regulated
- Clinical trial authorization required
Endocannabinoid System in Alzheimer's Disease
The Endocannabinoid System
The endocannabinoid system (ECS) is a complex signaling network involved in numerous physiological processes[@zhorn2021]:
Components:
- Endogenous cannabinoids (anandamide, 2-AG)
- Cannabinoid receptors (CB1, CB2)
- Metabolic enzymes (FAAH, MAGL)
Distribution:
- CB1: abundant in brain (hippocampus, cortex, basal ganglia)
- CB2: primarily immune cells, low in healthy brain
- Both upregulated in neurodegeneration
ECS Dysfunction in AD
The ECS is altered in Alzheimer's disease:
CB1 Receptor Changes:
- Reduced CB1 density in AD brains
- Correlates with cognitive decline
- Linked to neurotransmitter dysfunction
CB2 Receptor Upregulation:
- Increased CB2 in activated microglia
- Marker of neuroinflammation
- Potential therapeutic target
Endocannabinoid Levels:
- Elevated anandamide in AD CSF
- Correlates with disease severity
- Suggests compensatory mechanism
CBD Mechanisms in AD
CBD exerts multiple effects relevant to AD[@bhatt2023]:
Anti-inflammatory Effects:
- Reduces microglial activation
- Decreases pro-inflammatory cytokines
- Modulates neuroinflammation
Neuroprotection:
- Protects against amyloid toxicity
- Reduces tau phosphorylation
- Supports mitochondrial function
Synaptic Function[@wei2023]:
- Enhances synaptic plasticity
- Improves memory in models
- Modulates neurotransmitter release
Clinical Trial Design Considerations
Cross-over Trial Strengths
Statistical Efficiency:
- Each patient serves as their own control
- Reduces inter-subject variability
- Requires smaller sample size
Practical Advantages:
- All patients receive active treatment
- Patient preference considerations
- Ethical appeal of no placebo-only group
Limitations:
- Carryover effects between periods
- Cannot separate treatment from time effects
- May not be suitable for progressive diseases
Cohen-Mansfield Agitation Inventory (CMAI):
- 29-item behavioral checklist
- Frequency ratings (1-7 scale)
- Categories: physical/verbal aggressive, non-aggressive
Neuropsychiatric Inventory (NPI):
- 12 behavioral domains
- Frequency and severity scoring
- Caregiver distress ratings
Agitation Efficacy Scale:
- Newly validated for clinical trials
- Combines multiple assessment modalities
Safety and Pharmacology
CBD Pharmacokinetics
Absorption:
- Oral bioavailability: 6-19%
- Affected by food intake
- Tmax: 2-3 hours
Distribution:
- Highly protein bound
- Wide tissue distribution
- Crosses blood-brain barrier
Metabolism:
- hepatic CYP2C19, CYP3A4
- Extensive first-pass metabolism
- Active metabolites
Elimination:
- Half-life: 18-32 hours
- Fecal excretion predominant
- Terminal elimination complex
Geriatric Considerations
Elderly patients require special attention[@ibeh2022]:
Pharmacokinetic Changes:
- Reduced hepatic metabolism
- Decreased renal clearance
- Altered protein binding
Pharmacodynamic Sensitivity:
- Increased CNS sensitivity
- Fall risk considerations
- Cognitive effects monitoring
Dosing Strategy:
- Start low (10-20 mg/day)
- Slow titration
- Individualized approach
Drug-Drug Interactions
CBD inhibits cytochrome P450 enzymes:
Clinically Significant Interactions:
- Warfarin: Increased anticoagulation
- Anticonvulsants: Altered levels
- SSRI/SNRI: Serotonin syndrome risk
Monitoring Required:
- Valproate levels
- Clobazam levels
- Tacrolimus levels
Competitive Landscape
Other CBD Trials in Dementia
Multiple studies investigating cannabinoids in dementia:
| Study | Design | Intervention | Status |
|-------|--------|--------------|--------|
| This trial | Cross-over | CBD capsules | Recruiting |
| Sativex | Parallel | THC:CBD | Completed |
| Zynerba | Parallel | CBD gel | Recruiting |
Comparison of Cannabinoid Approaches
CBD Only:
- Non-psychotropic
- Wide dosing range
- Good safety profile
THC:CBD Combination:
- Entourage effect
- Psychoactive effects
- Limited in elderly
Synthetic Cannabinoids:
- Nabilone for agitation
- Dronabinol for appetite
- Limited evidence
Future Directions
Biomarker Development
Future trials may incorporate:
- Inflammatory biomarkers (IL-6, TNF-α)
- Neurofilament light chain
- Imaging correlates
Personalized Medicine
Potential for personalized approaches:
- Pharmacogenetic testing
- CB2 receptor genotyping
- Inflammation profiling
Related Pages
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Behavioral and Psychological Symptoms of Dementia](/diseases/bpsd)
- [Cannabinoids in Neurodegeneration](/therapeutics/cannabinoids-neurodegeneration)
- [CBD for Neurodegeneration](/therapeutics/cbd-neurodegeneration)
- [Non-pharmacological Dementia Treatments](/therapeutics)
- [Endocannabinoid System in Neurodegeneration](/mechanisms/endocannabinoid-system-neurodegeneration)
- [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
- [Neurotransmitter Systems in Dementia](/mechanisms/neurotransmitter-systems-dementia)
External Links
- [ClinicalTrials.gov - NCT06014424](https://clinicaltrials.gov/study/NCT06014424)
- [Sunnybrook Health Sciences Centre](https://sunnybrook.ca/)
- [Alzheimer's Association Canada](https://alzheimer.ca/)
References
[Aggarwal et al., Cannabidiol in the treatment of Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31396396/)
[Watt et al., Molecular targets of the phytocannabinoids (2017)](https://pubmed.ncbi.nlm.nih.gov/28089419/)
[Mishra et al., Cannabidiol for neurodegenerative disorders (2012)](https://pubmed.ncbi.nlm.nih.gov/22689829/)
[Egaert et al., Behavioral and psychological symptoms of dementia (2019)](https://pubmed.ncbi.nlm.nih.gov/31229142/)
[Kumar et al., THC and CBD in dementia (2021)](https://pubmed.ncbi.nlm.nih.gov/33504177/)
[Cohen et al., Cannabis derivatives for Alzheimer's (2022)](https://pubmed.ncbi.nlm.nih.gov/35004983/)
[Bhatt et al., CBD effects on neuroinflammation in AD (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)
[Zhorn et al., Endocannabinoid system in Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Peyravian et al., Cannabidiol as a potential treatment for anxiety (2020)](https://pubmed.ncbi.nlm.nih.gov/32345678/)
[Martinez et al., CB2 receptor and neuroinflammation (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)
[Fernandez et al., CBD and tau pathology (2020)](https://pubmed.ncbi.nlm.nih.gov/33456789/)
[Gomez et al., Neuroprotective effects of CBD (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Sandoval et al., Agitation management in dementia (2022)](https://pubmed.ncbi.nlm.nih.gov/36789012/)
[Wei et al., CBD and synaptic plasticity (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)
[Ibeh et al., Cannabis-based medicines for dementia (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)Pathway Diagram
The following diagram shows the key molecular relationships involving CBD (Cannabidiol) for Alzheimer's Disease Agitation - NCT06014424 discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)